Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

24

Full text

21

Free full text

8

Publication Types

Journal Article

24

Review

14

Research Support, Non-U.S. Gov't

11

Randomized Controlled Trial

3

Multicenter Study

3

Research Support, U.S. Gov't, Non-P.H.S.

2

Comparative Study

1

Clinical Trial, Phase II

1

Research Support, U.S. Gov't, P.H.S.

1

Observational Study

1

Research Support, N.I.H., Extramural

1

Publication Year

From

To

Quick links

Individual year

2018

3

2017

1

2016

1

2015

3

2014

3

2013

1

2010

1

2009

4

2008

1

2007

1

2006

4

2002

1

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Cathepsin K""[mesh_terms]

24 Results

Searching titles within these results

Design of cathepsin K inhibitors for osteoporosis.

Francis X Tavares, David N Deaton

Current topics in medicinal chemistry 2006;5(16):1639-75

The role of cathepsin X in cell signaling.

Janko Kos, Zala Jevnikar, Natasa Obermajer

Cell adhesion & migration 2009;3(2):164-6

The regulation of cathepsin K gene expression.

Bruce R Troen

Annals of the New York Academy of Sciences 2006;1068():165-72

3D-QSAR and docking studies of aldehyde inhibitors of human cathepsin K.

Xulin Pan, Ninghua Tan, Guangzhi Zeng, Hongjin Han, Huoqiang Huang

Bioorganic & medicinal chemistry 2006;14(8):2771-8

Intracellular signaling by cathepsin X: molecular mechanisms and diagnostic and therapeutic opportunities in cancer.

Janko Kos, Tjaša Vižin, Urša Pečar Fonović, Anja Pišlar

Seminars in cancer biology 2015;31():76-83

New Ru(ii) complex for dual photochemotherapy: release of cathepsin K inhibitor and O production.

Thomas N Rohrabaugh, Kelsey A Collins, Congcong Xue, Jessica K White, Jeremy J Kodanko, Claudia Turro

Dalton transactions (Cambridge, England : 2003) 2018;47(34):11851-11858

Established and forthcoming drugs for the treatment of osteoporosis.

Piet Geusens, Willem F Lems

Current opinion in rheumatology 2014;26(3):245-51

Future therapeutic targets in osteoporosis.

Chad Deal

Current opinion in rheumatology 2009;21(4):380-5

Anti-resorptive therapies for osteoporosis.

Ian R Reid

Seminars in cell & developmental biology 2009;19(5):473-8

Pain prediction by serum biomarkers of bone turnover in people with knee osteoarthritis: an observational study of TRAcP5b and cathepsin K in OA.

V B Kraus, L N Nwosu, M Allen, L Wyatt, J L Huebner, V Chapman, D A Walsh

Osteoarthritis and cartilage 2018;25(6):858-865

Novel advances in the treatment of osteoporosis.

Christopher K Y Chan, Alice Mason, Cyrus Cooper, Elaine Dennison

British medical bulletin 2017;119(1):129-42

Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.

Henry G Bone, Michael R McClung, Christian Roux, Robert R Recker, John A Eisman, Nadia Verbruggen, Carolyn M Hustad, Carolyn DaSilva, Arthur C Santora, B Avery Ince

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2010;25(5):937-47

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.

H G Bone, D W Dempster, J A Eisman, S L Greenspan, M R McClung, T Nakamura, S Papapoulos, W J Shih, A Rybak-Feiglin, A C Santora, N Verbruggen, A T Leung, A Lombardi

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2015;26(2):699-712

Short-term and long-term effects of osteoporosis therapies.

Ian R Reid

Nature reviews. Endocrinology 2016;11(7):418-28

Effect of a novel quaternary ammonium silane on dentin protease activities.

D Umer, C K Y Yiu, M F Burrow, L-N Niu, F R Tay

Journal of dentistry 2018;58():19-27

Results: 1 – 15 / 24

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.